Propargyl-PEG2-acid is a linker consisting of propargyl and carboxylic acid functional groups. In the presence of activators (e.g. EDC, or HATU), the carboxylic acid reacts with primary amine to form a stable amide bond. The propargyl group reacts with azide group in biomolecules to yield a stable triazole linkage. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.
Detail
Propargyl-PEG2-acid is a linker consisting of propargyl and carboxylic acid functional groups. In the presence of activators (e.g. EDC, or HATU), the carboxylic acid reacts with primary amine to form a stable amide bond. The propargyl group reacts with azide group in biomolecules to yield a stable triazole linkage. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.
Other Products
TD5 Table Top Low Speed Centrifuge
Product Info
Document
Product Info
Features:
1.Microprocessor control, digital display, touch panel, parameters in running can be edited and change to display other running parameter and RCF.
2.Brushless frequency motor with simpler construction, more reliable performance, longer life and quietly running.
3.Automatic lid lock, LCD display, It can store 100 programs. super speed, over temperature protection and imbalance protection. The centrifuge body is made of high quality steel, safe and reliable.
4.Adapters are available by experiment requirements.
5.3 tiers protection steel cover, safe and reliable.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non–small-cell lung cancer, melanoma, and renal-cell cancer.
p504s, also known as α-methylacyl coenzyme A racemase (AMACR), is an enzyme localized in the peroxisome and mitochondria, which functions in β-oxidation of branched chain fatty acids, as well as bile synthesis. AMACR has been clinically indicated as a tissue biomarker for prostate cancer and colorectal cancer, as well as high-grade prostatic intraepithelial neoplasia, a precursor lesion of prostate cancer. p504s overexpression has also been detected in a number of other cancers including ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma.